Evaluation of soluble mesothelin-related peptide as a marker additional to cytology for diagnosing malignant pleural mesothelioma effusions.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e17533-e17533
Author(s):  
Antonella Vigani ◽  
Paola Ferro ◽  
Pier Aldo Canessa ◽  
Enrico Battolla ◽  
Paolo Dessanti ◽  
...  
Keyword(s):  
Malignant Pleural Mesothelioma ◽  
Clinical Importance ◽  
Unknown Origin ◽  
Diagnostic Odds Ratio ◽  
Diagnostic Value ◽  
P Value ◽  
Pleural Mesothelioma ◽  
Chi Square ◽  
Related Peptide ◽  
Additional Value

e17533 Background: Detection of soluble mesothelin-related peptide (SMRP) levels in serum has been proposed to help the diagnosis of malignant pleural mesothelioma (MPM). In this study we evaluated the SMRP levels in pleural effusions of MPM (MPM-PE), the clinical importance and usefulness of SMRP detection in MPM-PE and whether it can have an additional value to cytological analysis (Cyt). Methods: We studied 52 MPM-PE, 129 benign PE (B-PE) and 94 non-MPM pleural metastasis PE (Mts-PE). In all PE samples, both cytology and SMRP detection were performed. SMRP levels were estimated by means of the MesoMark ELISA kit (Fujirebio Diagnostic, Malvern, PA). Diagnostic performance parameters were estimated through the ROC analysis, Youden's index was applied to obtain the best cut-off level and the degree of correlation was estimated by Diagnostic Odds Ratio (DOR) and by P-value (P) with Chi-square test. Results: The median SMRP levels were significantly higher in MPM-PE (28.2 nM) than in B-PE (3.2 nM) or Mts-PE (3.8 nM). MPM-PE vs B-PE yielded an AUC of 84.5 (P<0.001) whereas MPM-PE vs Mts-PE yelded an AUC of 79.6 (P<0.001). The cut off level in MPM-PE was estimated in 9.30 nM at which value we established Se=75%, Sp=93% for MPM-PE vs BPE and SP=81% for MPM-PE vs Mts-PE. We found SMRP positive cases (≥ cut off) in 38/52 (73%) MPM-PE, in 9/129 (7%) B-PE (DOR=40, P<0.001) and in 18/94 (19%) Mts-PE (DOR=13, P< 0.001).Cyt was negative in 29/52 (56%) of MPM-PE, among which SMRP was positive in 20/29 (69%) cases. Cyt was positive in 15/52 (29%) of MPM-PE, among which SMRP was negative in 4/15 (27%) cases. Finally, in 8/52 (15%) MPM-PE Cyt diagnosis was suspicious and SMRP was found positive in 7/8 (88%) cases. Conclusions: Our results demonstrate that SMRP levels in PE are significantly higher in MPM-PE than in PE from other pathologies. However the test cannot be alternative to cyt but it may provide additional diagnostic value to Cyt. SMRP detection in MPM-PE can be applied in the workup of patients with a PE of unknown origin.

scholarly journals Diagnostic value of soluble mesothelin-related peptides in pleural effusion for malignant pleural mesothelioma

Medicine ◽  
2019 ◽  
Vol 98 (14) ◽  
pp. e14979 ◽  
Author(s):  
Ruiyue Gao ◽  
Feng Wang ◽  
Zhen Wang ◽  
Yanbing Wu ◽  
Lili Xu ◽  
...  
Keyword(s):  
Pleural Effusion ◽  
Malignant Pleural Mesothelioma ◽  
Diagnostic Value ◽  
Pleural Mesothelioma

scholarly journals Diagnostic value of biopsy sampling in predicting histology in patients with diffuse malignant pleural mesothelioma

Cancer ◽  
2019 ◽  
Vol 125 (23) ◽  
pp. 4164-4171 ◽  
Author(s):  
Lucian R. Chirieac ◽  
Yin P. Hung ◽  
Wai Chin Foo ◽  
Matthias D. Hofer ◽  
Paul A. VanderLaan ◽  
...  
Keyword(s):  
Malignant Pleural Mesothelioma ◽  
Diagnostic Value ◽  
Pleural Mesothelioma ◽  
Diffuse Malignant Pleural Mesothelioma

scholarly journals Diagnostic value of fibulin-3 for malignant pleural mesothelioma: A systematic review and meta-analysis

Oncotarget ◽  
2016 ◽  
Vol 7 (51) ◽  
pp. 84851-84859 ◽  
Author(s):  
Ran Ren ◽  
Pengpeng Yin ◽  
Yan Zhang ◽  
Jianyun Zhou ◽  
Yixing Zhou ◽  
...  
Keyword(s):  
Systematic Review ◽  
Malignant Pleural Mesothelioma ◽  
Meta Analysis ◽  
Diagnostic Value ◽  
Pleural Mesothelioma

scholarly journals DNA Methylation of FKBP5 as Predictor of Overall Survival in Malignant Pleural Mesothelioma

Cancers ◽  
2020 ◽  
Vol 12 (11) ◽  
pp. 3470
Author(s):  
Giovanni Cugliari ◽  
Chiara Catalano ◽  
Simonetta Guarrera ◽  
Alessandra Allione ◽  
Elisabetta Casalone ◽  
...  
Keyword(s):  
Dna Methylation ◽  
Overall Survival ◽  
Malignant Pleural Mesothelioma ◽  
P Value ◽  
Pleural Mesothelioma ◽  
Lymphocyte To Monocyte Ratio ◽  
High Incidence ◽  
Aggressive Tumor ◽  
Independent Marker ◽  
The Relationship

Malignant pleural mesothelioma (MPM) is an aggressive tumor with median survival of 12 months and limited effective treatments. The scope of this study was to study the relationship between blood DNA methylation (DNAm) and overall survival (OS) aiming at a noninvasive prognostic test. We investigated a cohort of 159 incident asbestos exposed MPM cases enrolled in an Italian area with high incidence of mesothelioma. Considering 12 months as a cut-off for OS, epigenome-wide association study (EWAS) revealed statistically significant (p value = 7.7 × 10−9) OS-related differential methylation of a single-CpG (cg03546163), located in the 5′UTR region of the FKBP5 gene. This is an independent marker of prognosis in MPM patients with a better performance than traditional inflammation-based scores such as lymphocyte-to-monocyte ratio (LMR). Cases with DNAm < 0.45 at the cg03546163 had significantly poor survival compared with those showing DNAm ≥ 0.45 (mean: 243 versus 534 days; p value< 0.001). Epigenetic changes at the FKBP5 gene were robustly associated with OS in MPM cases. Our results showed that blood DNA methylation levels could be promising and dynamic prognostic biomarkers in MPM.

scholarly journals Diagnostic value of microRNAs for malignant pleural mesothelioma: A mini‐review

2020 ◽  
Vol 12 (1) ◽  
pp. 8-12
Author(s):  
Yan‐Qiu Han ◽  
Shang‐Cheng Xu ◽  
Wen‐Qi Zheng ◽  
Zhi‐De Hu
Keyword(s):  
Malignant Pleural Mesothelioma ◽  
Diagnostic Value ◽  
Pleural Mesothelioma

Novel malignant-mesothelioma-associated antigens (Gene-X and THBS-2) in the diagnosis of malignant pleural mesothelioma (MPM).

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 10585-10585
Author(s):  
Fumihiro Tanaka ◽  
Yoshiki Shigematsu ◽  
Takeshi Hanagiri ◽  
Hidetaka Uramoto ◽  
Tomoko So ◽  
...  
Keyword(s):  
Antibody Titer ◽  
Malignant Pleural Mesothelioma ◽  
Early Stage ◽  
Asbestos Exposure ◽  
Serum Antibody ◽  
Diagnostic Value ◽  
Pleural Mesothelioma ◽  
Roc Curve Analysis ◽  
Antibody Titers ◽  
Serum Antibody Titer

10585 Background: Malignant pleural mesothelioma (MPM) is a highly aggressive malignant tumor of the pleura associated with asbestos exposure, and its diagnosis is usually difficult at early stage. We identified novel mesothelioma-related antigens, Gene-X and thrombospondin-2 (THBS-2), recognized by tumor-infiltrating B cells (Cancer Sci 2009), but the clinical significance in the diagnosis of MPM remains unclear. Methods: A total of 120 patients, who presented with a suspicion of MPM and received pleural biopsy, were reviewed; 97 patients were finally diagnosed with MPM and 27 were with non-malignant diseases (NM). The antibody-titers against Gene-X and THBS-2 in the sera were measured by ELISA method. Results: The serum antibody-titer against THBS-2 was significantly higher in MPM patients than in NM (P<0.01), but there was no difference in the serum antibody-titer against Gene-X (Table). The receiver operating characteristic (ROC) curve analysis showed a significant diagnostic value of serum antibody-titer against THBS-2 with the area-under curve of 0.886 (95% CI, 0.797 - 0.975; P<0.001) in discrimination of MPM from NM diseases; the sensitivity and specificity, when the cut-off value was 0.08, were 72.2% and 95.5%, respectively. Conclusions: The serum antibody-titer against THBS-2 can be a useful non-invasive marker in the diagnosis of MPM. [Table: see text]

Role of CT and modified Response Evaluation Criteria in Solid Tumors (RECIST criteria) in response evaluation of malignant pleural mesothelioma

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Ass Prof .Dr., Khalid Esmat Allam ◽  
Hend Galal Eldeen Mohamed Ali Hassan ◽  
Basma Abdelbaset Mohamed
Keyword(s):  
Malignant Pleural Mesothelioma ◽  
Clinical Evaluation ◽  
Evaluation Criteria ◽  
Response Assessment ◽  
P Value ◽  
Pleural Mesothelioma ◽  
Response Evaluation ◽  
Malignant Pleural Mesothelioma Patient ◽  
Modified Recist

Abstract Background Malignant pleural mesothelioma is a rare and aggressive tumor that the growth pattern of it poses unique difficulties in measurement and response assessment . however, robust and reproducible assessment of response is critically important in the conduct, interpretation, and reporting of clinical trials. Objectives The aim of this study is to assess the value of CT and modified RECIST criteria in follow up patients of malignant pleural mesothelioma patient during treatment with chemotherapy . Patients and methods We evaluated 20 malignant pleural mesothelioma patients undergoing to chemotherapy . Tumor thickness is measures perpendicular to the chest wall or mediastinum in two positions at three separate levels on thoracic CT scans. The sum of the six measurements defined a pleural unidimensional measure. A reduction of at least 30% on two occasions 6 weeks apart defined a partial response; an increase of 20% over the nadir measurement known as progressive disease. Patients who fulfilled the criteria for neither PR nor PD called CD .The validity of the modified criteria was gauged by clinical evaluation . Results In our study, CT and modified RECIST criteria were used as the method of choice in response evaluation of malignant pleural mesothelioma .Our study showed as follow up results of each group and comparison between clinical evaluation and modified RECIST criteria show over all accuracy 73.3% with P value = 0.03 and this results confirm accuracy of CT with modified RECIST criteria as good predictor of disease outcome . Conclusion These Modified RECIST criteria for tumor response correlate with clinical evaluation and can be used to measure outcome in pleural mesothelioma.

scholarly journals ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma

2020 ◽  
Vol 55 (6) ◽  
pp. 1900953 ◽  
Author(s):  
Arnaud Scherpereel ◽  
Isabelle Opitz ◽  
Thierry Berghmans ◽  
Ioannis Psallidas ◽  
Markus Glatzer ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Malignant Pleural Mesothelioma ◽  
European Society ◽  
Radical Surgery ◽  
Task Force ◽  
Performance Status ◽  
Clinical Importance ◽  
Poor Performance Status ◽  
Pleural Mesothelioma ◽  
European Respiratory Society

The European Respiratory Society (ERS)/European Society of Thoracic Surgeons (ESTS)/European Association for Cardio-Thoracic Surgery (EACTS)/European Society for Radiotherapy and Oncology (ESTRO) task force brought together experts to update previous 2009 ERS/ESTS guidelines on management of malignant pleural mesothelioma (MPM), a rare cancer with globally poor outcome, after a systematic review of the 2009–2018 literature. The evidence was appraised using the Grading of Recommendations, Assessment, Development and Evaluation approach. The evidence syntheses were discussed and recommendations formulated by this multidisciplinary group of experts. Diagnosis: pleural biopsies remain the gold standard to confirm the diagnosis, usually obtained by thoracoscopy but occasionally via image-guided percutaneous needle biopsy in cases of pleural symphysis or poor performance status. Pathology: standard staining procedures are insufficient in ∼10% of cases, justifying the use of specific markers, including BAP-1 and CDKN2A (p16) for the separation of atypical mesothelial proliferation from MPM. Staging: in the absence of a uniform, robust and validated staging system, we advise using the most recent 2016 8th TNM (tumour, node, metastasis) classification, with an algorithm for pre-therapeutic assessment. Monitoring: patient's performance status, histological subtype and tumour volume are the main prognostic factors of clinical importance in routine MPM management. Other potential parameters should be recorded at baseline and reported in clinical trials. Treatment: (chemo)therapy has limited efficacy in MPM patients and only selected patients are candidates for radical surgery. New promising targeted therapies, immunotherapies and strategies have been reviewed. Because of limited data on the best combination treatment, we emphasise that patients who are considered candidates for a multimodal approach, including radical surgery, should be treated as part of clinical trials in MPM-dedicated centres.

scholarly journals P3.03-047 Diagnostic Value of Secretary Leukocyte Peptide Inhibitor (SLPI) in Pleural Fluid in Malignant Pleural Mesothelioma

2017 ◽  
Vol 12 (1) ◽  
pp. S1374-S1375
Author(s):  
Nobukazu Fujimoto ◽  
Kenji Takada ◽  
Yosuke Miyamoto ◽  
Michiko Asano ◽  
Yasuko Fuchimoto ◽  
...  
Keyword(s):  
Pleural Fluid ◽  
Malignant Pleural Mesothelioma ◽  
Diagnostic Value ◽  
Peptide Inhibitor ◽  
Pleural Mesothelioma

scholarly journals Protein Profiling of Pleural Effusions to Identify Malignant Pleural Mesothelioma Using SELDI-TOF MS

2009 ◽  
Vol 8 (5) ◽  
pp. 323-332 ◽  
Author(s):  
Joost P.J.J. Hegmans ◽  
Joris D. Veltman ◽  
Eric T. Fung ◽  
Thorsten Verch ◽  
Curtis Glover ◽  
...  
Keyword(s):  
Malignant Pleural Mesothelioma ◽  
Characteristic Curve ◽  
Diagnostic Value ◽  
Exchange Chromatography ◽  
Protein Profiling ◽  
Cytokeratin 19 ◽  
Pleural Mesothelioma ◽  
Pleural Effusions ◽  
Proteinchip Array ◽  
Potential Biomarker

Diagnosis of malignant pleural mesothelioma (MM) is limited. Novel proteomic technologies can be utilized to discover changes in expression of pleural proteins that might have diagnostic value. The objective of this study was to detect protein profiles that could be used to identify malignant pleural mesothelioma with surface enhanced laser desorption/ionization time-of-flight (SELDI-TOF) mass spectrometry (MS). Pleural effusions were collected from patients with confirmed mesothelioma (n = 41) and from patients with effusions due to other causes ([n = 48] cancerous and non-cancerous). Samples were fractionated using anion exchange chromatography and bound to different types of ProteinChip array surfaces. All samples were also subjected to other commercially available immunoassays (human epididymes protein 4 [HE4], osteopontin [OPN], soluble mesothelin-related proteins [SMRP], and the cytokeratin 19 fragment [CYFRA 21–1]). Peak intensity data obtained by SELDI-TOF were subjected to classification algorithms in order to identify potential classifier peaks. A protein peak at m/z 6614 was characterized as apolipoprotein (Apo) CI. In this setting, the sensitivity and specificity of this potential biomarker was 76 % and 69 %, respectively. The area under the receiver operating characteristic curve (AUC) for Apo CI was 0.755, thereby outperforming OPN, HE4, and CYFRA 21–1. SMRP performed best with an AUC of 0.860 with a sensitivity of 83% and specificity of 74%. Our study validates the use of SMRP as a diagnostic marker for pleural mesothelioma and furthermore suggests that Apo CI levels could be used in the future to discriminate pleural mesothelioma from other causes of exudates.

Sign in / Sign up

Export Citation Format

Share Document